Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Plaque Psoriasis

In brief

The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.

Key facts

Study ID

NCT02969018

Run by

Pfizer

People needed

212

Starts

2016-12-01

Expected to finish

2018-03-01

Last updated by the study team

2019-03-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline/Day 1 (prior to first dose of study drug)
• Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe") at Baseline/Day 1 (prior to first dose of study drug)
• Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at Baseline/Day 1 (prior to first dose of study drug)
• Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment)

You may not qualify if…

• Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed
• Have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis
• Cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA)
• Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).
• Have taken Apremilast (Otezla) within 3 months of first dose of study drug.
• Have undergone treatment with tofacitinib within 3 months of first dose.

Where it is running

• Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA — Rogers, Arkansas, United States
• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• California Dermatology & Clinical Research Institute — Encinitas, California, United States
• Emil A. Tanghetti, MD dba Center for Dermatology and Laser Surgery — Sacramento, California, United States
• Southern California Dermatology — Santa Ana, California, United States
• Tower Saint John's Imaging — Santa Monica, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Park Avenue Dermatology Administrative Annex — Orange Park, Florida, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• Olympian Clinical Research — Tampa, Florida, United States
• Rose Radiology — Tampa, Florida, United States
• Forward Clinical Trials, Inc — Tampa, Florida, United States
• Dundee Dermatology — West Dundee, Illinois, United States
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
• Dawes Fretzin Dermatology Group, LLC — Indianapolis, Indiana, United States
• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States
• The Rockefeller University — New York, New York, United States
• Skin Search of Rochester, Inc. — Rochester, New York, United States
• Investigational Drug Services, UNC Hospitals — Chapel Hill, North Carolina, United States
• UNC Dermatology and Skin Cancer Center — Chapel Hill, North Carolina, United States
• UNC Clinical and Translation Research Center — Chapel Hill, North Carolina, United States
• Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
• Vital Prospects Clinical Research Institute, P.C — Tulsa, Oklahoma, United States
• Health Concepts — Rapid City, South Dakota, United States
• Center for Clinical Studies — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.